<DOC>
	<DOCNO>NCT01192906</DOCNO>
	<brief_summary>This multi-center , randomize , double blind , parallel-group , placebo-controlled study evaluate efficacy safety RO4917838 ( bitopertin ) patient persistent , predominant negative symptom schizophrenia . Patients , stable treatment antipsychotic , randomize receive daily oral dos RO4917838 match placebo 52 week , follow optional treatment extension 3 year .</brief_summary>
	<brief_title>A Study RO4917838 ( Bitopertin ) Patients With Persistent , Predominant Negative Symptoms Schizophrenia ( WN25309 )</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Adult patient , age 18 year Diagnosis schizophrenia paranoid , disorganize , residual , undifferentiated catatonic subtype Predominant negative symptom With exception clozapine , patient available marketed atypical typical antipsychotic ( treatment maximum two antipsychotic ) Evidence patient clinically significant , uncontrolled unstable disorder ( e.g . cardiovascular , renal , hepatic disorder ) Body Mass Index ( BMI ) &lt; 17 &gt; 40 kg/m2 Depressive symptom , define score 9 great Calgary Depression Rating Scale Schizophrenia ( CDSS ) A severity score 3 great Parkinsonism item ESRSA ( Clinical Global Impression , Parkinsonism )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>